Want to see PHAT full AI Analyst Report?
PHAT Stock Chart & Stats
$13.19
-$0.22(-3.06%)
At close: 4:00 PM EST
$13.19
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$7.61 - $18.31
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.07M
Market Cap
$893.27M
Enterprise Value$862.71M
Total Cash (Recent Filing)$180.90M
Total Debt (Recent Filing)$166.30M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 06, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding79,755,950
10 Day Avg. Volume825,536
30 Day Avg. Volume1,068,847
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue4.21
Enterprise Value/Gross Profit4.96
Enterprise Value/Ebitda-9.49
Forecast
1Y Price Target
$24.25Price Target Upside83.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$334.03M
Bulls Say, Bears Say
Bulls Say
Rapid Prescription MomentumSustained and accelerating prescription volumes indicate durable commercial adoption among gastroenterologists and growing patient demand. High prescription density supports predictable net revenue scaling, enables more efficient sales ROI, and validates clinician preference that should sustain market share over the next several quarters.
High Product Gross MarginsVery high gross margins reflect favorable product economics typical of branded GI therapies and provide structural capacity to cover fixed commercial and R&D costs as revenue scales. This margin base improves the path to operating profitability and cash generation as prescription growth continues.
Markedly Reduced Leverage And Cash RunwayDramatic debt reduction and a sizable cash balance materially lower refinancing and interest risks. Improved liquidity supports the commercial rollout and ongoing EoE development without immediate financing, increasing operational resilience and allowing focused investment in sales coverage and clinical milestones.
Bears Say
Ongoing Negative Free Cash FlowPersistent negative operating and free cash flow signals the business still consumes cash to fund growth and operations. Until consistent positive cash generation arrives, the company remains dependent on liquidity management, which constrains discretionary investments and elevates funding or dilution risk over the medium term.
Negative Stockholders' EquityA materially negative equity position reflects cumulative losses and limits balance-sheet flexibility. This structural overhang can complicate capital-raising, deter certain partnerships, and increases the likelihood of equity issuance or other measures if cash flow targets slip, affecting long-term financial stability.
High Gross-to-net Discounts & Reimbursement VariabilityElevated gross-to-net deductions and a material share of cash-pay scripts create ongoing revenue dilution and quarter-to-quarter unpredictability. These structural reimbursement dynamics pressure realized net pricing and complicate forecasting and margin sustainability, especially if payer negotiations or channel mix shift unfavorably.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals, Inc.’s price range in the past 12 months?
Phathom Pharmaceuticals, Inc. lowest stock price was $7.61 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals, Inc.’s market cap?
Phathom Pharmaceuticals, Inc.’s market cap is $893.27M.
When is Phathom Pharmaceuticals, Inc.’s upcoming earnings report date?
Phathom Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 31 days.
How were Phathom Pharmaceuticals, Inc.’s earnings last quarter?
Phathom Pharmaceuticals, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.08.
Is Phathom Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Phathom Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Phathom Pharmaceuticals, Inc. pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
What is Phathom Pharmaceuticals, Inc.’s EPS estimate?
Phathom Pharmaceuticals, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Phathom Pharmaceuticals, Inc. have?
Phathom Pharmaceuticals, Inc. has 79,755,950 shares outstanding.
What happened to Phathom Pharmaceuticals, Inc.’s price movement after its last earnings report?
Phathom Pharmaceuticals, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -4.924%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.25 (83.85% Upside)
$24.25 (83.85% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 425.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.70%
12-Months-Change
Fundamentals
Return on Equity
39.24%
Trailing 12-Months
Asset Growth
3.71%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong commercial momentum and meaningful year-over-year growth, highlighted by rapid prescription uptake, high new-to-brand conversion among gastroenterologists, expanding sales coverage, an 80% gross margin, and ahead-of-schedule EoE enrollment. Management maintained guidance, reduced operating cash spend year-over-year, and ended the quarter with $181M in cash. Near-term challenges include Q1 being light versus internal expectations (seasonality and deployment timing), a modest sequential revenue increase (+1% vs Q4), an operating loss excluding stock-based compensation (~$9.9M), and persistent high gross-to-net discounts (55%–59% guidance) with variability due to channel mix. Competitive risk from a potential second P-CAB entrant in 2027 and a notable share of cash-pay prescriptions (~37% in Q1) remain considerations. On balance, the positives (robust growth, market share gains, commercial execution, clinical progress, and expense discipline) outweigh the near-term headwinds and uncertainties.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$24.25
▲(83.85% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
9.00% Insiders
13.25% Mutual Funds
49.77% Other Institutional Investors
18.94% Public Companies and
Individual Investors